Top Growth Trends in the Angina Pectoris Drugs Market: Key Insights and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Does the Projected Growth of the Angina Pectoris Drugs Market Compare Over the Forecast Period?
The market size for angina pectoris drugs has seen substantial growth in the past few years. The market is predicted to expand from $12.32 billion in 2024 to $12.94 billion in 2025, representing a compound annual growth rate (CAGR) of 5.1%. This growth during the historical period has been driven by the high incidence of cardiovascular diseases, an ageing population, lifestyle elements, a rise in hypertension, and the widespread prevalence of diabetes.
Expectations indicate a robust expansion of the angina pectoris drugs market in the coming years, predicting a growth to “$16.55 billion in 2029 with a compound annual growth rate (CAGR) of 6.3%. Factors propelling this projected growth within the forecast timeline include an increase in worldwide obesity rates, breakthroughs in precision medicine, emphasis on preventive cardiology, public awareness campaigns, and ongoing investigations into new therapeutic targets. Key tendencies anticipated during this forecast period are the use of telemedicine for distance monitoring, real-world proof and outcome studies, patient-focused drug education, strategic partnerships for market reach, regulatory progress, and expedited approvals.
Which Primary Drivers Are Supporting the Continued Expansion of the angina pectoris drugs Market?
The growing incidence of cardiovascular ailments is anticipated to fuel the expansion of the angina pectoris drug market. These diseases, encompassing varied disorders affecting the heart and blood vessels like coronary artery disease, hypertension, heart failure, and stroke, can be traced back to numerous causes such as an aging demographic, unhealthy lifestyles and the obesity crisis. Medications for angina pectoris, like nitrates, beta-blockers, and calcium channel blockers, efficiently alleviate the discomfort and chest pain ensuing from the heart’s inadequate blood supply, subsequently improving the patients’ overall life quality. For instance, the British Heart Foundation, a cardiovascular research charity based in the UK, stated in their September 2024 data that around 7.6 million individuals suffer from heart and circulatory diseases in the UK. These consist of approximately 4 million men and 3.6 million women. These ailments account for nearly 27% of all deaths in the UK, equivalent to over 170,000 fatalities every year, or almost 480 deaths daily, translating to one death every third minute. Consequently, the escalating incidence of cardiovascular diseases is propelling the angina pectoris drug market’s growth.
Explore Comprehensive Insights Into The Global Angina Pectoris Drugs Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp
Who Are the Key Players Steering the Development of the Angina Pectoris Drugs Market?
Major companies operating in the angina pectoris drugs market include:
• Astellas Pharma Inc._x000D_
• Bayer AG_x000D_
• Novartis AG_x000D_
• AstraZeneca PLC_x000D_
• Bausch Health Companies Inc._x000D_
How Are Consumer Trends Shaping the Current and Future Landscape of the Angina Pectoris Drugs Market?
The rise of product innovation is a noteworthy trend in the angina pectoris drugs market. Top firms in this sector are utilizing new technology to maintain their dominance. For instance, in March 2023, Hikma Pharmaceuticals PLC, a pharmaceutical company based in the UK, released the Labetalol Hydrochloride Injection, USP, in a prefilled syringe, with approval from the United States Food and Drug Administration. The product, which comes in a 10mg/2mL PFS dosage, is employed in hospitals to combat severe hypertension and to reduce blood pressure.
Secure Your Global Angina Pectoris Drugs Market Report Now for Fast and Efficient Delivery!
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
What Are the Strategic Segments Comprising the Angina Pectoris Drugs Market and Their Growth Contributions?
The angina pectoris drugs market covered in this report is segmented –
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates
2) By Antiplatelet Agents: Aspirin, Clopidogrel
3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers
5) By Anti-Ischemic Agents: Ranolazine, Ivabradine
6) By Statins: Atorvastatin, Rosuvastatin
Which Geographical Regions Are Shaping the Angina Pectoris Drugs Market Growth?
North America was the largest region in the angina pectoris drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
How Do Experts Define the Scope of the Angina Pectoris Drugs Market?
Angina pectoris drugs are medications used to treat angina pectoris, a medical illness that causes chest pain or discomfort when a portion of the heart does not receive enough blood and oxygen. Angina pectoris drugs treat chest pain or discomfort due to coronary heart disease.
Browse Through More Similar Reports By The Business Research Company:
Alzheimer’s Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Generic Central Nervous System Drugs Global Market Report 2024
Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
